AIM-listed ValiRx Plc (LON:VAL) said recruitment has concluded for an early-phase study of VAL401, a potential treatment for non-small cell lung cancer.
VAL-401 is being developed jointly by ValiRx and Tangent Reprofiling as part of the pair’s ValiSeek collaboration.
A total of eight patients with the disease will receive the drug and their results will be compared with 20 who aren’t on the new treatment.
READ: ValiRx story in full
Early data from the trial should be processed and analysed by the third-quarter, although ValiSeek can dose patients for up to six months.
This means the trial will be fully complete by the year-end following another round of processing and analysis.
Dr Suzy Dilly, chief executive of ValiSeek, said: "We are delighted to have been able to close on schedule, due to our confidence in the results that we are generating.
“Completion of recruitment and securing the untreated patient comparison data has been a big step forwards for our trial.
“The pharmacokinetic and safety data seen to date appears comparable to that expected and we are excited by and anticipate keenly the formal analysis of the data, so as to interpret and understand our observations more fully."